Physician profile
Michael C Diaz
NPI 1427040021
$1,462.86
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $224 · 2020: $204 · 2021: $225 · 2022: $522 · 2023: $288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $288.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $509.21 | 2019-2023 | Skyrizi, Creon, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $353.97 | 2020-2023 | Trulance, Xifaxan |
| Braintree Laboratories, INC. | $158.16 | 2022-2023 | Sutab, Suflave |
| Allergan, INC. | $68.61 | 2019-2020 | |
| Gilead Sciences, INC. | $61.19 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $53.98 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $41.19 | 2020-2023 | |
| Janssen Biotech, INC. | $35.31 | 2020-2022 | |
| Redhill Biopharma INC. | $33.21 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $29.69 | 2019 | |
| Merck Sharp & Dohme LLC | $27.72 | 2019-2022 | |
| Axonics, INC. | $25.77 | 2023 | Axonics |
| Romark Laboratories, Lc | $20.28 | 2020 | |
| Pfizer INC. | $17.74 | 2019 | |
| Celgene Corporation | $14.08 | 2023 | Zeposia |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $12.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Diaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.